title: Bipolaris hawaiiensis as etiologic agent of allergic bronchopulmonary mycosis: first case in a paediatric patient.
abstract: Allergic bronchopulmonary mycosis (ABPM) is a worldwide hypersensitivity lung disease of multiple etiologies with Aspergillus fumigatus as the most common etiologic agent. We report the first instance of Bipolaris hawaiiensis causing ABPM in a paediatric patient. A six-year-old girl presented in June 2009 with productive cough, exertional dyspnoea, occasional wheezing, restricted air entry in left infra-scapular and infra-axillary areas, 7% eosinophils (absolute count 540/mm(3)) and total IgE 1051.3 IU/m in the sera. Bronchoscopy revealed narrowing of left main bronchus and mucoid impaction of the left lower lobe segmental bronchi. Cytological examination of BAL revealed few eosinophils, Charcot-Leyden crystals and mucus embedded hyphae. Examination of KOH wet mounts of repeated sputum and BAL specimens revealed septate, brownish hyphae and culture of the specimens resulted in the isolation of multiple colonies of a fungus later identified as B. hawaiiensis based on phenotypic characters and sequencing of internal transcribed spacer and D1/D2 regions of rDNA. In addition, (1-3)-β-D-glucan was demonstrated in serum (316 pg/ml) by Fungitell kit, supportive of fungal infection/colonization. Histopathologic studies of a bronchial biopsy revealed necrotic debris, macrophage aggregates, lymphocytes, polymorphs and PAS positive hypae. The patient was administered oral itraconazole for 12 weeks, intravenous liposomal amphotericin B for one month, weekly bronchoscopic suctioning and voriconazole instillation, resulting in reduced mucopurulent secretions and considerable clinical improvement. A serum sample collected on 5 November demonstrated precipitins against antigens of the B. hawaiiensis isolate. In March 2010, intradermal skin testing revealed a strong, type I hypersensitivity (induration diam-12 mm) against B. hawaiiensis. The patient relapsed with wheezing and difficulty in respiration in April 2010. Considering the positive type I cutaneous hypersensitivity, the aforementioned laboratory and clinical observations, the patient was finally diagnosed as having ABPM and was successfully treated with oral prednisone. A high index of clinical suspicion with requisite investigations is crucial for early diagnosis and appropriate therapy of ABPM in order to prevent the late sequelae of irreversible broncho-pulmonary damage.
authors.affiliation: Department of Medical Mycology, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India. dranuradha@hotmail.com
authors.forename: Anuradha
authors.initials: A
authors.lastname: Chowdhary
authors.forename: Harbans S
authors.initials: HS
authors.lastname: Randhawa
authors.forename: Varinder
authors.initials: V
authors.lastname: Singh
authors.forename: Z U
authors.initials: ZU
authors.lastname: Khan
authors.forename: S
authors.initials: S
authors.lastname: Ahmad
authors.forename: Shallu
authors.initials: S
authors.lastname: Kathuria
authors.forename: P
authors.initials: P
authors.lastname: Roy
authors.forename: Geetika
authors.initials: G
authors.lastname: Khanna
authors.forename: Jagdish
authors.initials: J
authors.lastname: Chandra
mesh_terms: D000666:Amphotericin B / Q000008:administration & dosage; D000935:Antifungal Agents / Q000008:administration & dosage; D001203:Ascomycota / Q000302:isolation & purification*; D001232:Aspergillus fumigatus; D001980:Bronchi / Q000473:pathology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology / Q000382:microbiology; D001999:Bronchoscopy; D002648:Child; D004271:DNA, Fungal / Q000737:chemistry / Q000235:genetics; D004275:DNA, Ribosomal / Q000737:chemistry / Q000235:genetics; D021903:DNA, Ribosomal Spacer / Q000737:chemistry / Q000235:genetics; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D055744:Invasive Pulmonary Aspergillosis / Q000175:diagnosis* / Q000382:microbiology* / Q000473:pathology; D017964:Itraconazole / Q000008:administration & dosage; D008826:Microbial Sensitivity Tests; D008853:Microscopy; D008969:Molecular Sequence Data; D016533:Mycological Typing Techniques; D010802:Phylogeny; D011241:Prednisone / Q000008:administration & dosage; D011743:Pyrimidines / Q000008:administration & dosage; D017422:Sequence Analysis, DNA; D013183:Sputum / Q000166:cytology / Q000382:microbiology; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage; D065819:Voriconazole; D047071:beta-Glucans / Q000097:blood
chemical_list: D000935:Antifungal Agents; D004271:DNA, Fungal; D004275:DNA, Ribosomal; D021903:DNA, Ribosomal Spacer; D007166:Immunosuppressive Agents; D011743:Pyrimidines; D014230:Triazoles; D047071:beta-Glucans; C068538:liposomal amphotericin B; D017964:Itraconazole; D000666:Amphotericin B; C033363:beta-1,3-glucan; D065819:Voriconazole; D011241:Prednisone